Search
+
    SEARCHED FOR:

    OBESITY REASON

    On hottest days, risk of hospitalisation doubled in people having sugar, BP problems: Spanish study

    A study in Spain found that extreme heat doubles the risk of hospitalisation for people with metabolic disorders, obesity, and diabetes. Higher air pollution levels worsen the risk. Heat also affects blood pressure, leading to increased hospital admissions. Men are at higher risk for injuries, while women are at higher risk for infectious, hormonal, respiratory, and urinary diseases.

    Your go-to snack could pose hidden health risks

    A 30-year study published in British Medical Journal highlights the risks associated with high intake of ultra-processed foods, linking it to higher mortality rates. The study emphasizes the importance of following dietary guidelines, such as those from the Indian Council of Medical Research (ICMR), which promote whole foods for better health outcomes.

    Over 90% of US adults are highly susceptible to heart diseases, claim researchers

    A study has established the link between Cardiovascular-Kidney-Metabolic disorders and heart disease. Over 90% of the US Population is vulnerable.

    What would happen once we steered clear of sugar?

    ​Sugar is a class of naturally occurring sweet-tasting molecules found in fruits, vegetables, plants and the milk of mammals. It can be extracted from these natural sources and concentrated in processed foods.

    Covid-19 cases rising again in India: Experts cite this reason and precautions

    Delhi recorded 63 new Covid-19 cases, marking the highest daily number since May last year. Other northern states like Rajasthan, Uttar Pradesh, and Bihar are also experiencing a rise in cases. Over the past 15 days, Delhi reported a total of 459 cases. Experts believe that the actual count is likely much higher due to low testing rates. The northern states are witnessing a spike in cases, while Karnataka is experiencing a decline.

    Eli Lilly could launch obesity drug in India next year, CEO says

    Eli Lilly plans to launch its diabetes and obesity drug, Mounjaro, in India next year. The drug contains tirzepatide and is sold as Zepbound in the US. The global market for GLP-1 receptor agonists, including Mounjaro, Wegovy, and Ozempic, is expected to reach $100 billion by the end of the decade. Lilly's drugs as well as Danish rival Novo Nordisk's in-demand Wegovy and Ozempic are therapies known as GLP-1 receptor agonists, which were developed to control blood sugar in patients with type 2 diabetes.

    The Economic Times
    BACK TO TOP